Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20535549 | 0.95 | RET (1.00) | RETKDR | |
| SCHEMBL20534945 | 0.93 | RET (1.00) | RETKDR | |
| SCHEMBL20534892 | 0.93 | RET (1.00) | RETKDR | |
| SCHEMBL29678033 | 0.93 | RET (1.00) | RETKDR | |
| SCHEMBL20535280 | 0.92 | RET (1.00) | RETKDR | |
| SCHEMBL20534900 | 0.92 | RET (1.00) | RETKDR | |
| SCHEMBL21958124 | 0.90 | RET (1.00) | RETKDR | |
| SCHEMBL29904394 | 0.90 | RET (1.00) | RETKDR | |
| SCHEMBL20534967 | 0.89 | RET (1.00) | RETKDR | |
| SCHEMBL20535572 | 0.89 | RET (1.00) | RETKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243202-A1 | Compounds Useful as RET Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-31 | — | — | US | claimed |
| US-20240132504-A1 | Compounds Useful as RET Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-04-25 | — | — | US | claimed |
| CN-110506043-B | Compounds useful as RET inhibitors | 癌症研究科技有限公司 | 2022-11-01 | — | — | CN | claimed |
| US-11352361-B2 | Compounds useful as RET inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-06-07 | — | — | US | claimed |
| EP-3609898-B1 | COMPOUNDS USEFUL AS RET INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2022-06-01 | — | — | EP | claimed |
| US-20200157107-A1 | Compounds Useful as RET Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-21 | — | — | US | claimed |
| EP-3609898-A1 | COMPOUNDS USEFUL AS RET INHIBITORS | Cancer Research Technology Limited (GB) | 2020-02-19 | — | — | EP | claimed |
| WO-2018189553-A1 | COMPOUNDS USEFUL AS RET INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-10-18 | — | — | WO | claimed |
| US-20250243202-A1 | Compounds Useful as RET Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-31 | — | — | US | disclosed |
| CN-115785100-B | Compounds useful as RET inhibitors | 癌症研究科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240132504-A1 | Compounds Useful as RET Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-04-25 | — | — | US | disclosed |
| US-11680068-B2 | Compounds useful as RET inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-06-20 | — | — | US | disclosed |
| US-11680068-B2 | Compounds useful as RET inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-06-20 | — | — | US | disclosed |
| US-11680068-B2 | Compounds useful as RET inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-06-20 | — | — | US | disclosed |
| EP-3609898-B1 | COMPOUNDS USEFUL AS RET INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2022-06-01 | — | — | EP | disclosed |
| EP-3609898-B1 | COMPOUNDS USEFUL AS RET INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2022-06-01 | — | — | EP | disclosed |
| US-20200157107-A1 | Compounds Useful as RET Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-21 | — | — | US | disclosed |
| US-20200157107-A1 | Compounds Useful as RET Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-21 | — | — | US | disclosed |
| EP-3609898-A1 | COMPOUNDS USEFUL AS RET INHIBITORS | Cancer Research Technology Limited (GB) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018189553-A1 | COMPOUNDS USEFUL AS RET INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243202-A1 | Compounds Useful as RET Inhibitors | RET, BCR, REL | RET 1/4885KDR 542/4885 |
| US-11352361-B2 | Compounds useful as RET inhibitors | RET, BCR, REL | RET 1/4885KDR 542/4885 |
| US-20200157107-A1 | Compounds Useful as RET Inhibitors | RET, BCR, REL | RET 1/4885KDR 542/4885 |
| US-20240132504-A1 | Compounds Useful as RET Inhibitors | RET, BCR, REL | RET 1/4885KDR 542/4885 |
| US-11680068-B2 | Compounds useful as RET inhibitors | RET, BCR, REL | RET 1/4885KDR 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.